Project Details
| Short title | AMT-562-01 |
|---|---|
| Acronym | AMT-562-01 |
| Status | Active |
| Effective start/end date | 25/03/24 → 26/02/29 |
CTU: First-in-Human, Phase 1 Study of AMT-562, an Anti-HER3 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
- Sabanathan, Dhanusha (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Chester, Catherine (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
- Martin, Lewis (Clinical Trial Unit Staff)
Project: Research